Log in with your email address username.


[Comment] Filling the gaps in COPD: the TRIBUTE study

Chronic obstructive pulmonary disease (COPD) is a major public health problem because of its high prevalence (about 10% of the adult population), rising incidence (COPD is predicted to be the third global cause of death by 2020), and high associated personal, social, and economic costs.1 Regular physical activity, appropriate vaccination, and avoiding toxic exposures (eg, tobacco smoking) are important non-pharmacological approaches for the management of patients with COPD.1 Meanwhile, pharmacological treatment for COPD is fundamentally based on the use of inhaled drugs: long-acting bronchodilators (long-acting antimuscarinic agents, long-acting β2 agonists, or both), with or without inhaled corticosteroids.